Literature DB >> 8174838

Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance.

R R Little1, J D England, H M Wiedmeyer, R W Madsen, D J Pettitt, W C Knowler, D E Goldstein.   

Abstract

Glycated haemoglobin could offer several practical advantages over the OGTT for assessing glucose metabolism. Initial cross-sectional studies (1983-1985) on 381 subjects (mostly Pima Indians) described the relationship between HbA1c (a specific glycated Hb) and the OGTT. We performed follow-up OGTTs and HbA1c measurements on 257 of these same subjects 1.6-6.1 years later. Subjects were again grouped according to both the result of the OGTT (normal, IGT or diabetes, by WHO criteria) and HbA1c result (normal or elevated based on mean +/- 1.96 SD of normal). Of 66 subjects with IGT at baseline, 47 (71%) had normal HbA1c and 19 (29%) had elevated HbA1c. Twenty-six (39%) of these subjects had diabetes at follow-up. Of these subjects with IGT, a significantly greater percentage of subjects with elevated HbA1c at baseline (68%) showed worsening to diabetes than those with a normal HbA1c (28%); (chi-square = 7.8, df = 1, p < 0.01). Thus, in subjects with IGT, glycated Hb may be a useful predictor of progression to diabetes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8174838     DOI: 10.1007/bf00398051

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  20 in total

1.  Glycosylated hemoglobin assay and oral glucose tolerance test compared for detection of diabetes mellitus.

Authors:  R F Dods; C Bolmey
Journal:  Clin Chem       Date:  1979-05       Impact factor: 8.327

2.  Glycosylated hemoglobins: increased glycosylation of hemoglobin A in diabetic patients.

Authors:  K H Gabbay; J M Sosenko; G A Banuchi; M J Mininsohn; R Flückiger
Journal:  Diabetes       Date:  1979-04       Impact factor: 9.461

Review 3.  Diabetes mellitus. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1985

4.  Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. The DCCT Research Group.

Authors: 
Journal:  Clin Chem       Date:  1987-12       Impact factor: 8.327

5.  Bimodality of glycosylated hemoglobin distribution in Pima Indians: relationship to fasting hyperglycemia.

Authors:  E V Flock; P H Bennett; P J Savage; C J Webner; B V Howard; N B Rushforth; M Miller
Journal:  Diabetes       Date:  1979-11       Impact factor: 9.461

6.  Glycosylated hemoglobin determination from capillary blood samples. Utility in an epidemiologic survey of diabetes.

Authors:  R E Ferrell; C L Hanis; L Aguilar; B Tulloch; C Garcia; W J Schull
Journal:  Am J Epidemiol       Date:  1984-02       Impact factor: 4.897

7.  Glycosylated hemoglobins and glycosylated plasma proteins in the diagnosis of diabetes mellitus and impaired glucose tolerance.

Authors:  P M Hall; J G Cook; J Sheldon; S M Rutherford; B J Gould
Journal:  Diabetes Care       Date:  1984 Mar-Apr       Impact factor: 19.112

8.  HbA1 in subjects with abnormal glucose tolerance but normal fasting plasma glucose.

Authors:  G Bolli; P Compagnucci; M G Cartechini; F Santeusanio; C Cirotto; L Scionti; P Brunetti
Journal:  Diabetes       Date:  1980-04       Impact factor: 9.461

Review 9.  The clinical utility of glycosylated hemoglobin.

Authors:  L Jovanovic; C M Peterson
Journal:  Am J Med       Date:  1981-02       Impact factor: 4.965

10.  Haemoglobin A1: An indicator of the metabolic control of diabetic patients.

Authors:  B Gonen; A Rubenstein; H Rochman; S P Tanega; D L Horwitz
Journal:  Lancet       Date:  1977-10-08       Impact factor: 79.321

View more
  10 in total

1.  Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes.

Authors:  Jukka Montonen; Dagmar Drogan; Hans-Georg Joost; Heiner Boeing; Andreas Fritsche; Erwin Schleicher; Matthias B Schulze; Tobias Pischon
Journal:  Eur J Epidemiol       Date:  2010-12-28       Impact factor: 8.082

2.  Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women.

Authors:  Aruna D Pradhan; Nader Rifai; Julie E Buring; Paul M Ridker
Journal:  Am J Med       Date:  2007-08       Impact factor: 4.965

3.  Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study.

Authors:  G Nijpels; C Popp-Snijders; P J Kostense; L M Bouter; R J Heine
Journal:  Diabetologia       Date:  1996-01       Impact factor: 10.122

Review 4.  Insulin resistance syndrome in children : pathophysiology and potential management strategies.

Authors:  Tamás Decsi; Dénes Molnár
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

5.  Glucose tolerance in patients with cystic fibrosis: five year prospective study.

Authors:  S Lanng; A Hansen; B Thorsteinsson; J Nerup; C Koch
Journal:  BMJ       Date:  1995-09-09

6.  International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 17.152

Review 7.  A1C level and future risk of diabetes: a systematic review.

Authors:  Xuanping Zhang; Edward W Gregg; David F Williamson; Lawrence E Barker; William Thomas; Kai McKeever Bullard; Giuseppina Imperatore; Desmond E Williams; Ann L Albright
Journal:  Diabetes Care       Date:  2010-07       Impact factor: 19.112

8.  Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria in the european prospective investigation of cancer-norfolk cohort: implications for preventive strategies.

Authors:  Parinya Chamnan; Rebecca K Simmons; Nita G Forouhi; Robert N Luben; Kay-Tee Khaw; Nicholas J Wareham; Simon J Griffin
Journal:  Diabetes Care       Date:  2010-07-09       Impact factor: 19.112

9.  Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year follow-up in the ADDITION study, Denmark.

Authors:  S S Rasmussen; C Glümer; A Sandbaek; T Lauritzen; K Borch-Johnsen
Journal:  Diabetologia       Date:  2007-12-05       Impact factor: 10.122

10.  Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program.

Authors:  David Preiss; Sofia Zetterstrand; John J V McMurray; Jan Ostergren; Eric L Michelson; Christopher B Granger; Salim Yusuf; Karl Swedberg; Marc A Pfeffer; Hertzel C Gerstein; Naveed Sattar
Journal:  Diabetes Care       Date:  2009-02-05       Impact factor: 19.112

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.